A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.

Atsuro SaijoHirokazu OginoNicholas A ButowskiMeghan R TedescoDavid GibsonPayal B WatchmakerKaori OkadaAlbert S WangAnny ShaiAndres M SalazarAnnette M MolinaroJane E RabbittMaryam ShahinArie PerryJennifer L Clarke Jennie W TaylorMariza DarasNancy Ann Oberheim BushShawn L Hervey-JumperJoanna J PhillipsSusan M ChangNorbert HilfAndrea Mayer-MoklerTibor KelerMitchel S BergerHideho Okada

Published in: Neuro-oncology (2023)

The combinational immunotherapy, including varlilumab, was well-tolerated and induced vaccine-reactive T-cell expansion in the peripheral blood but without a detectable response in the tumor. Further developments of strategies to overcome the blood-tumor barrier are warranted to improve the efficacy of immunotherapy for LGG patients.

Keyphrases

peripheral blood
low grade
high grade
end stage renal disease
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
working memory
dendritic cells
oxidative stress
patient reported outcomes
patient reported